サイトカイン療法 Cytokine Therapies : Novel Approaches for Clinical Indications (Annals of the New York Academy of Sciences)

サイトカイン療法<br>Cytokine Therapies : Novel Approaches for Clinical Indications (Annals of the New York Academy of Sciences)

個数：

サイトカイン療法
Cytokine Therapies : Novel Approaches for Clinical Indications (Annals of the New York Academy of Sciences)

Donnelly, Raymond P. (EDT)

ウェブストア価格 ¥30,993（本体¥28,176）
Blackwell Pub（2010/01発売）
外貨定価 US$ 149.75
ポイント 281pt

在庫がございません。海外の書籍取次会社を通じて出版社等からお取り寄せいたします。
通常6～9週間ほどで発送の見込みですが、商品によってはさらに時間がかかることもございます。
【重要ご説明事項】
1. 納期遅延や、ご入手不能となる場合がございます。
2. 複数冊ご注文の場合、分割発送となる場合がございます。
3. 美品のご指定は承りかねます。

●3Dセキュア導入とクレジットカードによるお支払いについて

【入荷遅延について】
世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。

◆画像の表紙や帯等は実物とは異なる場合があります。

◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
また、洋書販売価格は、ご注文確定時点での日本円価格となります。
ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。

製本 Paperback:紙装版/ペーパーバック版／ページ数 160 p.
言語 ENG
商品コード 9781573317832
DDC分類 571

基本説明

Examines the scientific and clinical basis for the successes and failures of recombinant cytokines and cytokine antagonists as therapeutic agents, and possible strategies for improving their clinical success.

Full Description

Cytokines are protein messengers responsible for cellular communication with great therapeutic potential to control inflammatory and immune disorders such us cancer, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Despite the solid scientific rationale for this therapeutic promise, many cytokine-related therapies have failed to establish clinical utility. In March 2009, international experts from academia, industry and government convened to discuss the scientific and clinical basis for the successes and failures of recombinant cytokines and cytokine antagonists as therapeutic agents, and possible strategies for improving their clinical success. This volume included extended versions of key presentations at the meeting.

Participants examined:
• Improved methods for identifying disease targets
• Alternative methods for enhancing and targeting cytokine delivery
• Physicochemical modification of cytokines to prolong their bioavailability

NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit www.blackwellpublishing.com/nyas.

ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to the Annals online and discounts on print volumes. Please visit http://www.nyas.org/MemberCenter/Join.aspx for more information about becoming a member.

An overview of cytokines and cytokine antagonists as therapeutic agents 1 Pharmacologic administration of interleukin-2: inducing a systemic autophagic syndrome? 14

Perspective on potential clinical applications of recombinant human interleukin-7 28

Immune modulation with interleukin-21 39

Clinical and immunologic basis of interferon therapy in melanoma 47

Heterogeneous, longitudinally stable molecular signatures in response to interferon-beta 58

Clinical use of interferon-gamma 69

Interferon lambda as a potential new therapeutic for hepatitis C 80

Cytokines as targets for anti-inflammatory agents 88

Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases 97

Blocking interleukin-1 in rheumatic diseases: its initial disappointments and recent successes in the treatment of autoinflammatory diseases 111

Rilonacept: CAPS and beyond, a scientific journey 124

Actobiotics as a novel method for cytokine delivery: the interleukin-10 case 135

Hurdles and leaps for protein therapeutics: cytokines and inflammation 146